# Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

> **NCT00274742** · PHASE1 · COMPLETED · sponsor: **Amgen Research (Munich) GmbH** · enrollment: 76 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma, Relapsed

## Interventions

- **BIOLOGICAL:** Blinatumomab (MT103)

## Key facts

- **NCT ID:** NCT00274742
- **Lead sponsor:** Amgen Research (Munich) GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2011-08
- **Final completion:** 2012-04
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2015-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274742, "Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00274742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*